Circulating Type 2 Memory B Cell Frequency Is a Biomarker for Allergen Immunotherapy Efficacy in Patients With Allergic Rhinitis.
To the Editor, Reliable early biomarkers are needed to monitor allergen immunotherapy (AIT) efficacy in allergic rhinitis (AR). Type 2 memory B cells, marked by IL‐4Rα and CD23, are implicated in antigen‐specific Immunoglobulin E (IgE) production and promote enhanced antigen recall responses in allergic disease [1, 2]. However, the precise dynamics of type 2 memory B (MBC2) cells during AIT remain poorly understood and their potential utility as candidate biomarkers for treatment monitoring has...